Exciting BD Opportunities for Molecular Glues and PROTACs!
A publicly listed Chinese pharmaceutical company is actively sourcing molecular glue and PROTAC programs targeting solid tumors with unrestricted target scope. We welcome assets ranging from IND-enabling stage through ongoing Phase 1 clinical trials. Both global rights and Greater China rights are of interest to us.
Pharmaceutical companies holding relevant assets are encouraged to contact the DrugTimes BD team without delay!
Email: BD@drugtimes.cn
Sincerely thank you.
发布者：DrugTimes001，转载请首先联系contact@drugtimes.cn获得授权
为好文打赏 支持药时代 共创新未来！ 
